Influenza
Conditions
Keywords
influenza infection, GSK Biologicals' influenza vaccine GSK2340272A
Brief summary
This trial will assess the immunogenicity and safety elicited by the adjuvanted GSK Biologicals' influenza investigational vaccine GSK2340274A in healthy Japanese adults aged 20-64 years.
Detailed description
This Protocol Posting has been updated following Protocol amendment 1& 2, October 2009. The sections impacted are study design and outcome measures
Interventions
BIOLOGICALInfluenza investigational vaccine GSK2340274A
Two intramuscular injections on Day 0 and Day 21, respectively
Sponsors
GlaxoSmithKline
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 64 Years
Healthy volunteers
Yes
Inclusion criteria
* Japanese male and female adults 20 to 64 years of age at time of the first vaccination, inclusive. * Good general health as assessed by medical history and physical examination * Subjects who the investigator believes that they can and will comply with the requirements of the protocol. * Written informed consent obtained from the subject. * Access to a consistent means of telephone contact, which may be either in the home or at the workplace, land line or mobile, but NOT a pay phone or other multiple-user device. * Females of non-childbearing potential may be enrolled in the study. * Female of childbearing potential may be enrolled in the study, if she: * has practiced adequate contraception for 30 days prior to vaccination, and * has a negative pregnancy test on the day of vaccination, and * has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.
Exclusion criteria
* Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period. * History of previous administration of a novel \[H1N1\]v vaccine. * Previous participation in study NCT00742885. * Presence of significant acute or chronic, uncontrolled medical or psychiatric illness. * Presence or evidence of substance abuse or of neurological or psychiatric diagnoses which, although stable, are deemed by the investigator to render the potential subject unable/unlikely to provide accurate safety reports. * Presence of an axillary temperature \>= 37.5 °C, or acute symptoms greater than mild severity on the scheduled date of first vaccination. * Diagnosed with cancer, or treatment for cancer within 3 years. * Any confirmed or suspected immunosuppressive or immunodeficient condition including history of human immunodeficiency virus (HIV) infection. * Chronic administration of immunosuppressants or other immune modifying drugs within 6 months of study enrolment or planned administration during the study period. * Receipt of any immunoglobulins and/or any blood products within 3 months of study enrolment or planned administration of any of these products during the study period. * Any significant disorder of coagulation or treatment with warfarin derivatives or heparin. * An acute evolving neurological disorder or history of Guillain-Barré syndrome. * Administration of any vaccines within 30 days before vaccination or planned administration within the first vaccination up to blood sampling at Day 42 and within 30 days prior to blood sampling at Day 182, with the exception of seasonal influenza vaccine. * Administration of any seasonal influenza vaccine within 14 days before vaccination on Day 0, or planned administration within the first vaccination up to blood sampling at Day 42 and within 14 days prior to blood sampling at Day 182. * Any known or suspected allergy to any constituent of influenza vaccines or component used in the manufacturing process of the study vaccine; a history of anaphylactic-type reaction to any constituent of influenza vaccines; or a history of severe adverse reaction to a previous influenza vaccine. * Known pregnancy or a positive urine test result prior to the time of first vaccination. * Lactating or nursing female. * Excessive underweight (Body Mass Index \[BMI\] \< 18.5) or excessive obesity (BMI \>= 30). * Any conditions which, in the opinion of the investigator, prevents the subjects from participating in the study. * Clinically or virologically confirmed influenza infection within 6 months preceding the study start.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen | At Day 0 | Titers are presented as geometric mean titers (GMTs). |
| Number of Seropositive Subjects for Haemagglutination Inhibition (HI) Antibodies A/California/7/2009 (H1N1)V-like Antigen | At Day 0 | A seropositive subject was defined as a subject whose serum antibody titer was greater than or equal to (≥) 1:10. |
| Number of Seropositive Subjects for Haemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen | At Day 21 | A seropositive subject was defined as a subject whose serum antibody titer was greater than or equal to (≥) 1:10. |
| Number of Seroconverted Subjects for Haemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen | At Day 21 | A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer smaller than (\<) 1:10 and a post-vaccination titer greater than or equal to (≥) 1:40 or a pre-vaccination titer ≥ 1:10 and at least a four-fold increase in post-vaccination titer. |
| Number of Seroprotected Subjects Against A/California/7/2009 (H1N1)V-like Antigen | At Day 0 | A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40. |
| Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen | At Day 21 | The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Seropositive Subjects for Neutralizing Antibodies Against A/Neth/602/09 (H1N1)V-like Antigen | At Days 0, 21, 42 and 182 | A seropositive subject was defined as a subject whose serum antibody titer was greater than or equal to (≥) 1:8. |
| Number of Seroconverted Subjects for Neutralizing Antibodies Against A/Neth/602/09 (H1N1)V-like Antigen | At Days 21, 42 and 182 | A seroconverted subject was defined as a vaccinated subject with a minimum 4-fold increase in post vaccination neutralizing titer. |
| Number of Subjects With Any and Grade 3 Solicited Local Symptoms | During a 7-day (Days 0-6) follow-up after each vaccination | Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. |
| Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | During a 7-day (Days 0-6) follow-up after each vaccination | Assessed solicited general symptoms were fatigue, headache, joint pain at other location, muscle aches, shivering, sweating and temperature \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 temperature = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination. |
| Number of Seropositive Subjects for Haemagglutination Inhibition (HI) Antibodies A/California/7/2009 (H1N1)V-like Antigen | At Days 0, 21, 42 and 182 | A seropositive subject was defined as a subject whose serum antibody titer was greater than or equal to (≥) 1:10. |
| Number of Subjects With Serious Adverse Events (SAEs) | During the entire study period (Days 0-182) | Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. |
| Number of Subjects With Any Adverse Events of Specific Interest (AESIs). | During the entire study period (Days 0-182) | An AESI was defined as an AE including autoimmune diseases and other mediated inflammatory disorders and assessed by the investigator as specific to the treatment administration. |
| Number of Days With Any Solicited Local Symptoms | During a 7-day (Days 0-6) follow-up after each vaccination | Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. The number of days with any solicited local symptom was assessed in subjects who have reported at least once the symptom. |
| Number of Days With Any Solicited General Symptoms | During a 7-day (Days 0-6) follow-up after each vaccination | Assessed solicited general symptoms were fatigue, headache, joint pain at other location, muscle aches, shivering, sweating and temperature \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. The number of days with any solicited general symptom was assessed in subjects who have reported at least once the symptom. |
| Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | During a 21-day (Days 0-20) follow-up period after the first vaccination and during a 63-day (Days 21-84) follow-up after the second vaccination | An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination. |
| Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen | At Days 0, 21, 42 and 182 | Titers are presented as geometric mean titers (GMTs). |
| Number of Seroconverted Subjects for Haemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen | At Days 21, 42 and 182 | A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer smaller than (\<) 1:10 and a post-vaccination titer greater than or equal to (≥) 1:40 or a pre-vaccination titer ≥ 1:10 and at least a four-fold increase in post-vaccination titer. |
| Number of Seroprotected Subjects Against A/California/7/2009 (H1N1)V-like Antigen | At Days 0, 21, 42 and 182 | A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40. |
| Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen | At Days 21, 42 and 182 | The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0. |
| Titers for Serum Neutralizing Antibodies Against A/Neth/602/09 (H1N1)V-like Antigen | At Days 0, 21, 42 and 182 | Titers are presented as geometric mean titers (GMTs). |
Countries
Japan
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| GSK2340274A Group Healthy subjects, aged 20 to 64 years, male and female, received 2 doses of GSK2340274A vaccine, injected intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21. | 100 |
| Total | 100 |
Baseline characteristics
| Characteristic | GSK2340274A Group |
|---|---|
| Age, Continuous | 39.3 Years STANDARD_DEVIATION 11.65 |
| Sex: Female, Male Female | 64 Participants |
| Sex: Female, Male Male | 36 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 100 |
| other Total, other adverse events | 100 / 100 |
| serious Total, serious adverse events | 2 / 100 |
Outcome results
Primary
Number of Seroconverted Subjects for Haemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen
A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer smaller than (\<) 1:10 and a post-vaccination titer greater than or equal to (≥) 1:40 or a pre-vaccination titer ≥ 1:10 and at least a four-fold increase in post-vaccination titer.
Time frame: At Day 42
Population: Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects, who received the 2 vaccine doses and for whom assay results for antibodies against vaccine antigen were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| GSK2340274A Group | Number of Seroconverted Subjects for Haemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen | 100 Participants |
Primary
Number of Seroconverted Subjects for Haemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen
A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer smaller than (\<) 1:10 and a post-vaccination titer greater than or equal to (≥) 1:40 or a pre-vaccination titer ≥ 1:10 and at least a four-fold increase in post-vaccination titer.
Time frame: At Day 21
Population: Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects, who received the 2 vaccine doses and for whom assay results for antibodies against vaccine antigen were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| GSK2340274A Group | Number of Seroconverted Subjects for Haemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen | 94 Participants |
Primary
Number of Seropositive Subjects for Haemagglutination Inhibition (HI) Antibodies A/California/7/2009 (H1N1)V-like Antigen
A seropositive subject was defined as a subject whose serum antibody titer was greater than or equal to (≥) 1:10.
Time frame: At Day 0
Population: Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects, who received the 2 vaccine doses and for whom assay results for antibodies against vaccine antigen were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| GSK2340274A Group | Number of Seropositive Subjects for Haemagglutination Inhibition (HI) Antibodies A/California/7/2009 (H1N1)V-like Antigen | 43 Participants |
Primary
Number of Seropositive Subjects for Haemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen
A seropositive subject was defined as a subject whose serum antibody titer was greater than or equal to (≥) 1:10.
Time frame: At Day 21
Population: Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects, who received the 2 vaccine doses and for whom assay results for antibodies against vaccine antigen were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| GSK2340274A Group | Number of Seropositive Subjects for Haemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen | 100 Participants |
Primary
Number of Seropositive Subjects for Haemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen
A seropositive subject was defined as a subject whose serum antibody titer was greater than or equal to (≥) 1:10.
Time frame: At Day 42
Population: Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects, who received the 2 vaccine doses and for whom assay results for antibodies against vaccine antigen were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| GSK2340274A Group | Number of Seropositive Subjects for Haemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen | 100 Participants |
Primary
Number of Seroprotected Subjects Against A/California/7/2009 (H1N1)V-like Antigen
A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40.
Time frame: At Day 42
Population: Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects, who received the 2 vaccine doses and for whom assay results for antibodies against vaccine antigen were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| GSK2340274A Group | Number of Seroprotected Subjects Against A/California/7/2009 (H1N1)V-like Antigen | 100 Participants |
Primary
Number of Seroprotected Subjects Against A/California/7/2009 (H1N1)V-like Antigen
A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40.
Time frame: At Day 21
Population: Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects, who received the 2 vaccine doses and for whom assay results for antibodies against vaccine antigen were available
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| GSK2340274A Group | Number of Seroprotected Subjects Against A/California/7/2009 (H1N1)V-like Antigen | 95 Participants |
Primary
Number of Seroprotected Subjects Against A/California/7/2009 (H1N1)V-like Antigen
A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40.
Time frame: At Day 0
Population: Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects, who received the 2 vaccine doses and for whom assay results for antibodies against vaccine antigen were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| GSK2340274A Group | Number of Seroprotected Subjects Against A/California/7/2009 (H1N1)V-like Antigen | 6 Participants |
Primary
Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen
The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0.
Time frame: At Day 42
Population: Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects, who received the 2 vaccine doses and for whom assay results for antibodies against vaccine antigen were available.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| GSK2340274A Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen | 55.4 Fold change |
Primary
Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen
The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0.
Time frame: At Day 21
Population: Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects, who received the 2 vaccine doses and for whom assay results for antibodies against vaccine antigen were available.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| GSK2340274A Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen | 26.3 Fold change |
Primary
Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen
Titers are presented as geometric mean titers (GMTs).
Time frame: At Day 21
Population: Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects, who received the 2 vaccine doses and for whom assay results for antibodies against vaccine antigen were available.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| GSK2340274A Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen | 230.3 Titers |
Primary
Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen
Titers are presented as geometric mean titers (GMTs).
Time frame: At Day 0
Population: Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects, who received the 2 vaccine doses and for whom assay results for antibodies against vaccine antigen were available.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| GSK2340274A Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen | 8.8 Titers |
Primary
Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen
Titers are presented as geometric mean titers (GMTs).
Time frame: At Day 42
Population: Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects, who received the 2 vaccine doses and for whom assay results for antibodies against vaccine antigen were available.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| GSK2340274A Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen | 485.0 Titers |
Secondary
Number of Days With Any Solicited General Symptoms
Assessed solicited general symptoms were fatigue, headache, joint pain at other location, muscle aches, shivering, sweating and temperature \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. The number of days with any solicited general symptom was assessed in subjects who have reported at least once the symptom.
Time frame: During a 7-day (Days 0-6) follow-up after each vaccination
Population: Analysis was performed on the Total Vaccinated Cohort which included all vaccinated subjects.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| GSK2340274A Group | Number of Days With Any Solicited General Symptoms | Joint pain at other location, Dose 2 | 2 Days |
| GSK2340274A Group | Number of Days With Any Solicited General Symptoms | Headache, Dose 1 | 1 Days |
| GSK2340274A Group | Number of Days With Any Solicited General Symptoms | Fatigue, Dose 1 | 2 Days |
| GSK2340274A Group | Number of Days With Any Solicited General Symptoms | Joint pain at other location, Dose 1 | 2 Days |
| GSK2340274A Group | Number of Days With Any Solicited General Symptoms | Muscle aches, Dose 1 | 3 Days |
| GSK2340274A Group | Number of Days With Any Solicited General Symptoms | Sweating, Dose 1 | 1 Days |
| GSK2340274A Group | Number of Days With Any Solicited General Symptoms | Shivering, Dose 1 | 1 Days |
| GSK2340274A Group | Number of Days With Any Solicited General Symptoms | Temperature, Dose 1 | 1 Days |
| GSK2340274A Group | Number of Days With Any Solicited General Symptoms | Fatigue, Dose 2 | 2 Days |
| GSK2340274A Group | Number of Days With Any Solicited General Symptoms | Headache, Dose 2 | 1 Days |
| GSK2340274A Group | Number of Days With Any Solicited General Symptoms | Muscle aches, Dose 2 | 3 Days |
| GSK2340274A Group | Number of Days With Any Solicited General Symptoms | Sweating, Dose 2 | 1 Days |
| GSK2340274A Group | Number of Days With Any Solicited General Symptoms | Shivering, Dose 2 | 1 Days |
| GSK2340274A Group | Number of Days With Any Solicited General Symptoms | Temperature, Dose 2 | 1 Days |
Secondary
Number of Days With Any Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. The number of days with any solicited local symptom was assessed in subjects who have reported at least once the symptom.
Time frame: During a 7-day (Days 0-6) follow-up after each vaccination
Population: Analysis was performed on the Total Vaccinated Cohort which included all vaccinated subjects.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| GSK2340274A Group | Number of Days With Any Solicited Local Symptoms | Pain, Dose 1 | 4 Days |
| GSK2340274A Group | Number of Days With Any Solicited Local Symptoms | Redness, Dose 1 | 3 Days |
| GSK2340274A Group | Number of Days With Any Solicited Local Symptoms | Swelling, Dose 1 | 3 Days |
| GSK2340274A Group | Number of Days With Any Solicited Local Symptoms | Pain, Dose 2 | 3 Days |
| GSK2340274A Group | Number of Days With Any Solicited Local Symptoms | Redness, Dose 2 | 3 Days |
| GSK2340274A Group | Number of Days With Any Solicited Local Symptoms | Swelling, Dose 2 | 3 Days |
Secondary
Number of Seroconverted Subjects for Haemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen
A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer smaller than (\<) 1:10 and a post-vaccination titer greater than or equal to (≥) 1:40 or a pre-vaccination titer ≥ 1:10 and at least a four-fold increase in post-vaccination titer.
Time frame: At Days 21, 42 and 182
Population: Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects, who received the 2 vaccine doses and for whom assay results for antibodies against vaccine antigen were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK2340274A Group | Number of Seroconverted Subjects for Haemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen | Day 182 | 48 Participants |
| GSK2340274A Group | Number of Seroconverted Subjects for Haemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen | Day 21 | 50 Participants |
| GSK2340274A Group | Number of Seroconverted Subjects for Haemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen | Day 42 | 50 Participants |
| GSK2340274A 41-64Y Group | Number of Seroconverted Subjects for Haemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen | Day 21 | 44 Participants |
| GSK2340274A 41-64Y Group | Number of Seroconverted Subjects for Haemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen | Day 42 | 50 Participants |
| GSK2340274A 41-64Y Group | Number of Seroconverted Subjects for Haemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen | Day 182 | 45 Participants |
Secondary
Number of Seroconverted Subjects for Neutralizing Antibodies Against A/Neth/602/09 (H1N1)V-like Antigen
A seroconverted subject was defined as a vaccinated subject with a minimum 4-fold increase in post vaccination neutralizing titer.
Time frame: At Days 21, 42 and 182
Population: Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects, who received the 2 vaccine doses and for whom assay results for antibodies against vaccine antigen were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK2340274A Group | Number of Seroconverted Subjects for Neutralizing Antibodies Against A/Neth/602/09 (H1N1)V-like Antigen | Day 42 | 48 Participants |
| GSK2340274A Group | Number of Seroconverted Subjects for Neutralizing Antibodies Against A/Neth/602/09 (H1N1)V-like Antigen | Day 21 | 39 Participants |
| GSK2340274A Group | Number of Seroconverted Subjects for Neutralizing Antibodies Against A/Neth/602/09 (H1N1)V-like Antigen | Day 182 | 42 Participants |
| GSK2340274A 41-64Y Group | Number of Seroconverted Subjects for Neutralizing Antibodies Against A/Neth/602/09 (H1N1)V-like Antigen | Day 42 | 48 Participants |
| GSK2340274A 41-64Y Group | Number of Seroconverted Subjects for Neutralizing Antibodies Against A/Neth/602/09 (H1N1)V-like Antigen | Day 21 | 35 Participants |
| GSK2340274A 41-64Y Group | Number of Seroconverted Subjects for Neutralizing Antibodies Against A/Neth/602/09 (H1N1)V-like Antigen | Day 182 | 34 Participants |
Secondary
Number of Seropositive Subjects for Haemagglutination Inhibition (HI) Antibodies A/California/7/2009 (H1N1)V-like Antigen
A seropositive subject was defined as a subject whose serum antibody titer was greater than or equal to (≥) 1:10.
Time frame: At Days 0, 21, 42 and 182
Population: Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects, who received the 2 vaccine doses and for whom assay results for antibodies against vaccine antigen were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK2340274A Group | Number of Seropositive Subjects for Haemagglutination Inhibition (HI) Antibodies A/California/7/2009 (H1N1)V-like Antigen | Day 21 | 50 Participants |
| GSK2340274A Group | Number of Seropositive Subjects for Haemagglutination Inhibition (HI) Antibodies A/California/7/2009 (H1N1)V-like Antigen | Day 0 | 22 Participants |
| GSK2340274A Group | Number of Seropositive Subjects for Haemagglutination Inhibition (HI) Antibodies A/California/7/2009 (H1N1)V-like Antigen | Day 182 | 50 Participants |
| GSK2340274A Group | Number of Seropositive Subjects for Haemagglutination Inhibition (HI) Antibodies A/California/7/2009 (H1N1)V-like Antigen | Day 42 | 50 Participants |
| GSK2340274A 41-64Y Group | Number of Seropositive Subjects for Haemagglutination Inhibition (HI) Antibodies A/California/7/2009 (H1N1)V-like Antigen | Day 182 | 50 Participants |
| GSK2340274A 41-64Y Group | Number of Seropositive Subjects for Haemagglutination Inhibition (HI) Antibodies A/California/7/2009 (H1N1)V-like Antigen | Day 0 | 21 Participants |
| GSK2340274A 41-64Y Group | Number of Seropositive Subjects for Haemagglutination Inhibition (HI) Antibodies A/California/7/2009 (H1N1)V-like Antigen | Day 42 | 50 Participants |
| GSK2340274A 41-64Y Group | Number of Seropositive Subjects for Haemagglutination Inhibition (HI) Antibodies A/California/7/2009 (H1N1)V-like Antigen | Day 21 | 50 Participants |
Secondary
Number of Seropositive Subjects for Neutralizing Antibodies Against A/Neth/602/09 (H1N1)V-like Antigen
A seropositive subject was defined as a subject whose serum antibody titer was greater than or equal to (≥) 1:8.
Time frame: At Days 0, 21, 42 and 182
Population: Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects, who received the 2 vaccine doses and for whom assay results for antibodies against vaccine antigen were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK2340274A Group | Number of Seropositive Subjects for Neutralizing Antibodies Against A/Neth/602/09 (H1N1)V-like Antigen | Day 42 | 50 Participants |
| GSK2340274A Group | Number of Seropositive Subjects for Neutralizing Antibodies Against A/Neth/602/09 (H1N1)V-like Antigen | Day 0 | 24 Participants |
| GSK2340274A Group | Number of Seropositive Subjects for Neutralizing Antibodies Against A/Neth/602/09 (H1N1)V-like Antigen | Day 21 | 47 Participants |
| GSK2340274A Group | Number of Seropositive Subjects for Neutralizing Antibodies Against A/Neth/602/09 (H1N1)V-like Antigen | Day 182 | 50 Participants |
| GSK2340274A 41-64Y Group | Number of Seropositive Subjects for Neutralizing Antibodies Against A/Neth/602/09 (H1N1)V-like Antigen | Day 182 | 49 Participants |
| GSK2340274A 41-64Y Group | Number of Seropositive Subjects for Neutralizing Antibodies Against A/Neth/602/09 (H1N1)V-like Antigen | Day 42 | 50 Participants |
| GSK2340274A 41-64Y Group | Number of Seropositive Subjects for Neutralizing Antibodies Against A/Neth/602/09 (H1N1)V-like Antigen | Day 21 | 49 Participants |
| GSK2340274A 41-64Y Group | Number of Seropositive Subjects for Neutralizing Antibodies Against A/Neth/602/09 (H1N1)V-like Antigen | Day 0 | 27 Participants |
Secondary
Number of Seroprotected Subjects Against A/California/7/2009 (H1N1)V-like Antigen
A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40.
Time frame: At Days 0, 21, 42 and 182
Population: Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects, who received the 2 vaccine doses and for whom assay results for antibodies against vaccine antigen were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK2340274A Group | Number of Seroprotected Subjects Against A/California/7/2009 (H1N1)V-like Antigen | Day 0 | 3 Participants |
| GSK2340274A Group | Number of Seroprotected Subjects Against A/California/7/2009 (H1N1)V-like Antigen | Day 21 | 50 Participants |
| GSK2340274A Group | Number of Seroprotected Subjects Against A/California/7/2009 (H1N1)V-like Antigen | Day 42 | 50 Participants |
| GSK2340274A Group | Number of Seroprotected Subjects Against A/California/7/2009 (H1N1)V-like Antigen | Day 182 | 49 Participants |
| GSK2340274A 41-64Y Group | Number of Seroprotected Subjects Against A/California/7/2009 (H1N1)V-like Antigen | Day 182 | 46 Participants |
| GSK2340274A 41-64Y Group | Number of Seroprotected Subjects Against A/California/7/2009 (H1N1)V-like Antigen | Day 0 | 3 Participants |
| GSK2340274A 41-64Y Group | Number of Seroprotected Subjects Against A/California/7/2009 (H1N1)V-like Antigen | Day 42 | 50 Participants |
| GSK2340274A 41-64Y Group | Number of Seroprotected Subjects Against A/California/7/2009 (H1N1)V-like Antigen | Day 21 | 45 Participants |
Secondary
Number of Subjects With Any Adverse Events of Specific Interest (AESIs).
An AESI was defined as an AE including autoimmune diseases and other mediated inflammatory disorders and assessed by the investigator as specific to the treatment administration.
Time frame: During the entire study period (Days 0-182)
Population: Analysis was performed on the Total Vaccinated Cohort which included all vaccinated subjects.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| GSK2340274A Group | Number of Subjects With Any Adverse Events of Specific Interest (AESIs). | 0 Participants |
Secondary
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
Time frame: During a 7-day (Days 0-6) follow-up after each vaccination
Population: Analysis was performed on the Total Vaccinated Cohort which included all vaccinated subjects.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK2340274A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Swelling, Any, Dose 1 | 17 Participants |
| GSK2340274A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Swelling, Grade 3, Dose 2 | 1 Participants |
| GSK2340274A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Swelling, Any, Across doses | 24 Participants |
| GSK2340274A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Pain, Any, Dose 1 | 98 Participants |
| GSK2340274A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Pain, Grade 3, Dose 1 | 3 Participants |
| GSK2340274A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Redness, Any, Dose 1 | 7 Participants |
| GSK2340274A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Redness, Grade 3, Dose 1 | 1 Participants |
| GSK2340274A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Swelling, Grade 3, Dose 1 | 2 Participants |
| GSK2340274A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Pain, Any, Dose 2 | 93 Participants |
| GSK2340274A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Pain, Grade 3, Dose 2 | 2 Participants |
| GSK2340274A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Redness, Any, Dose 2 | 8 Participants |
| GSK2340274A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Redness, Grade 3, Dose 2 | 0 Participants |
| GSK2340274A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Swelling, Any, Dose 2 | 17 Participants |
| GSK2340274A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Pain, Any, Across doses | 99 Participants |
| GSK2340274A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Pain, Grade 3, Across doses | 5 Participants |
| GSK2340274A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Redness, Any, Across doses | 13 Participants |
| GSK2340274A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Redness, Grade 3, Across doses | 1 Participants |
| GSK2340274A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Swelling, Grade 3, Across doses | 2 Participants |
Secondary
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
Assessed solicited general symptoms were fatigue, headache, joint pain at other location, muscle aches, shivering, sweating and temperature \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 temperature = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
Time frame: During a 7-day (Days 0-6) follow-up after each vaccination
Population: Analysis was performed on the Total Vaccinated Cohort which included all vaccinated subjects.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Shivering, Any, Dose 1 | 19 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Sweating, Any, Dose 1 | 7 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Muscle aches, Grade 3, Dose 2 | 0 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Temperature (Axillary), Any, Dose 2 | 7 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Fatigue, Any, Dose 1 | 46 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Fatigue, Grade 3, Dose 1 | 2 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Fatigue, Related, Dose 1 | 45 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Headache, Any, Dose 1 | 35 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Headache, Grade 3, Dose 1 | 1 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Headache, Related, Dose 1 | 34 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Joint pain at other location, Any, Dose 1 | 14 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Joint pain at other location, Grade 3, Dose 1 | 0 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Joint pain at other location, Related, Dose 1 | 14 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Muscle aches, Any, Dose 1 | 44 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Muscle aches, Grade 3, Dose 1 | 1 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Muscle aches, Related, Dose 1 | 44 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Shivering, Grade 3, Dose 1 | 0 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Shivering, Related, Dose 1 | 19 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Sweating, Grade 3, Dose 1 | 0 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Sweating, Related, Dose 1 | 7 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Temperature (Axillary), Any, Dose 1 | 2 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Temperature (Axillary), Grade 3, Dose 1 | 0 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Temperature (Axillary), Related, Dose 1 | 2 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Fatigue, Any, Dose 2 | 54 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Fatigue, Grade 3, Dose 2 | 3 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Fatigue, Related, Dose 2 | 54 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Headache, Any, Dose 2 | 39 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Headache, Grade 3, Dose 2 | 2 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Headache, Related, Dose 2 | 37 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Joint pain at other location, Any, Dose 2 | 30 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Joint pain at other location, Grade 3, Dose 2 | 1 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Joint pain at other location, Related, Dose 2 | 30 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Muscle aches, Any, Dose 2 | 51 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Muscle aches, Related, Dose 2 | 51 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Shivering, Any, Dose 2 | 29 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Shivering, Grade 3, Dose 2 | 4 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Shivering, Related, Dose 2 | 29 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Sweating, Any, Dose 2 | 9 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Sweating, Grade 3, Dose 2 | 0 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Sweating, Related, Dose 2 | 9 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Temperature (Axillary), Grade 3, Dose 2 | 1 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Temperature (Axillary), Related, Dose 2 | 6 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Fatigue, Any, Across doses | 69 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Fatigue, Grade 3, Across doses | 5 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Fatigue, Related, Across doses | 68 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Headache, Any, Across doses | 51 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Headache, Grade 3, Across doses | 3 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Headache, Related, Across doses | 49 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Joint pain at other location, Any, Across doses | 33 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Joint pain at other location, Grade 3, Across dose | 1 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Joint pain at other location, Related, Across dose | 33 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Muscle aches, Any, Across doses | 59 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Muscle aches, Grade 3, Across doses | 1 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Muscle aches, Related, Across doses | 59 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Shivering, Any, Across doses | 37 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Shivering, Grade 3, Across doses | 4 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Shivering, Related, Across doses | 37 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Sweating, Any, Across doses | 13 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Sweating, Grade 3, Across doses | 0 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Sweating, Related, Across doses | 13 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Temperature (Axillary), Any, Across doses | 7 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Temperature (Axillary), Grade 3, Across doses | 1 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Temperature (Axillary), Related, Across doses | 6 Participants |
Secondary
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
Time frame: During a 21-day (Days 0-20) follow-up period after the first vaccination and during a 63-day (Days 21-84) follow-up after the second vaccination
Population: Analysis was performed on the Total Vaccinated Cohort which included all vaccinated subjects.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Subjects with any AE(s) | 46 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Subjects with grade 3 AE(s) | 1 Participants |
| GSK2340274A Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Subjects with related AE(s) | 18 Participants |
Secondary
Number of Subjects With Serious Adverse Events (SAEs)
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: During the entire study period (Days 0-182)
Population: Analysis was performed on the Total Vaccinated Cohort which included all vaccinated subjects.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| GSK2340274A Group | Number of Subjects With Serious Adverse Events (SAEs) | 2 Participants |
Secondary
Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen
The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0.
Time frame: At Days 21, 42 and 182
Population: Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects, who received the 2 vaccine doses and for whom assay results for antibodies against vaccine antigen were available.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK2340274A Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen | Day 21 | 29.1 Fold change |
| GSK2340274A Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen | Day 42 | 57.0 Fold change |
| GSK2340274A Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen | Day 182 | 20.6 Fold change |
| GSK2340274A 41-64Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen | Day 21 | 23.8 Fold change |
| GSK2340274A 41-64Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen | Day 42 | 53.9 Fold change |
| GSK2340274A 41-64Y Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen | Day 182 | 19.4 Fold change |
Secondary
Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen
Titers are presented as geometric mean titers (GMTs).
Time frame: At Days 0, 21, 42 and 182
Population: Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects, who received the 2 vaccine doses and for whom assay results for antibodies against vaccine antigen were available.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK2340274A Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen | Day 21 | 258.3 Titers |
| GSK2340274A Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen | Day 42 | 505.6 Titers |
| GSK2340274A Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen | Day 0 | 8.9 Titers |
| GSK2340274A Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen | Day 182 | 182.6 Titers |
| GSK2340274A 41-64Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen | Day 21 | 205.3 Titers |
| GSK2340274A 41-64Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen | Day 182 | 167.9 Titers |
| GSK2340274A 41-64Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen | Day 0 | 8.9 Titers |
| GSK2340274A 41-64Y Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen | Day 42 | 465.3 Titers |
Secondary
Titers for Serum Neutralizing Antibodies Against A/Neth/602/09 (H1N1)V-like Antigen
Titers are presented as geometric mean titers (GMTs).
Time frame: At Days 0, 21, 42 and 182
Population: Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects, who received the 2 vaccine doses and for whom assay results for antibodies against vaccine antigen were available.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK2340274A Group | Titers for Serum Neutralizing Antibodies Against A/Neth/602/09 (H1N1)V-like Antigen | Day 42 | 336.6 Titers |
| GSK2340274A Group | Titers for Serum Neutralizing Antibodies Against A/Neth/602/09 (H1N1)V-like Antigen | Day 0 | 8.7 Titers |
| GSK2340274A Group | Titers for Serum Neutralizing Antibodies Against A/Neth/602/09 (H1N1)V-like Antigen | Day 182 | 133.5 Titers |
| GSK2340274A Group | Titers for Serum Neutralizing Antibodies Against A/Neth/602/09 (H1N1)V-like Antigen | Day 21 | 146.6 Titers |
| GSK2340274A 41-64Y Group | Titers for Serum Neutralizing Antibodies Against A/Neth/602/09 (H1N1)V-like Antigen | Day 182 | 98.0 Titers |
| GSK2340274A 41-64Y Group | Titers for Serum Neutralizing Antibodies Against A/Neth/602/09 (H1N1)V-like Antigen | Day 21 | 127.8 Titers |
| GSK2340274A 41-64Y Group | Titers for Serum Neutralizing Antibodies Against A/Neth/602/09 (H1N1)V-like Antigen | Day 0 | 8.4 Titers |
| GSK2340274A 41-64Y Group | Titers for Serum Neutralizing Antibodies Against A/Neth/602/09 (H1N1)V-like Antigen | Day 42 | 277.7 Titers |